Probing the mechanistic basis for T cell fate decisions (R01)
探讨T细胞命运决定的机制基础(R01)
基本信息
- 批准号:10088367
- 负责人:
- 金额:$ 40.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-08-10 至 2023-01-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAntigen-Presenting CellsArchitectureAttenuatedAutomobile DrivingBehaviorBindingBiological AssayBiomedical EngineeringBiosensorCD3 AntigensCD4 Positive T LymphocytesCRISPR/Cas technologyCell membraneCellular ImmunityCellular biologyComplexCytokine ReceptorsDataDetectionDevelopmentDimerizationEPOR geneEctopic ExpressionEngineeringEnzymesExtracellular DomainFluorescence Recovery After PhotobleachingFluorescence Resonance Energy TransferFrequenciesFundingGoalsHealthHumanITAMImageImmunityImmunotherapeutic agentImpairmentIn SituIn VitroIndividualInstructionLinkMapsMechanicsMediatingMediator of activation proteinMembraneMolecularMolecular MachinesMusPeptide/MHC ComplexPeptidesPhosphorylationPhosphotransferasesPositioning AttributeProteinsReagentRegulatory T-LymphocyteReportingScanningSideSignal TransductionSpecificitySurfaceSurveysSystemT cell responseT-Cell ActivationT-Cell ReceptorT-LymphocyteTestingTherapeuticTransgenic MiceTransmembrane DomainTumor-DerivedWorkbasechimeric antigen receptordesignencryptionexperimental analysisextracellularin vivoinsightintravital imagingmicrobialmutantnovelpathogenic microbereceptorrecruitresponsespatial relationshipsrc-Family Kinasestumor
项目摘要
TITLE: Probing the mechanistic basis for T cell fate decisions.
CD4+ T cells use highly sensitive and specific modular biosensors to survey the body for microbial pathogens
or tumors. The TCR is the chief mediator of this behavior. It surveys the contents of MHC on antigen
presenting cells for peptides (pMHC) derived from microbial pathogens or tumors, and relays pMHC-specific
information across the cell membrane to the ten immunoreceptor tyrosine-based activation motifs (ITAMs) of
the associated CD3γε , CD3δε, and CD3ζζ signaling modules. CD4 recruits Lck to the TCR-CD3 complex upon
concurrent binding of MHC. The quantity and quality of ITAM phosphorylation by Lck provides the base set of
instructions that inform CD4+ T cell fate decision. Yet, how the individual subunits of the TCR-CD3-pMHC-CD4
macro-complex fit and work together to drive CD4+ T cell fate decisions remains to be fully defined. Our
working hypothesis is that these molecules operate on a similar mechanistic principle to less complex receptor
systems, such as cytokine receptors, whereby receptor-associated intracellular signaling enzymes and their
substrates are held in a spatial relationship that represents “off”; pMHC-engagement and reciprocal
extracellular interactions between the TCR-CD3 complex and CD4 then positions the intracellular signaling
domains in the appropriate spatial relationship for a sufficient duration to initiate and potentiate signaling. Our
overarching goal is understand the inner workings of this complex molecular machinery so that we can modify
or imitate its form and function to design novel modular biosensors with unique therapeutic functions. During
the previous funding period we built multiple experimental platforms to study the spatial relationship between
the juxtamembrane (JM) regions of the TCR-CD3 subunits. These allowed us to report the identification of a
mechanical switch that relays pMHC-specific information from the TCR-pMHC interface across the T cell
membrane to the cytosolic juxtamembrane regions of the CD3ζζ signaling module. In addition, we performed
the first experimental analysis of the architecture of the TCR-CD3-pMHC-CD4 macrocomplex and found that
the CD4 JM region is proximal to the CD3 heterodimers, while CD3ζζ resides on the opposite side of the TCR.
We also identified highly conserved residues in the TMD and extracellular domains of CD4 that are important
for CD4's Lck-independent and Lck-dependent functions. Finally, we obtained functional evidence for TCR-
intrinsic specificity for MHC that we interpret as evidence for MHC scanning. The goals for this renewal
application are to deconstruct the molecular mechanisms by which the TCR-CD3-pMHC-CD4 macrocomplex
operates and characterize the consequences of these mechanisms in vivo. Our work will yield fundamental
insights into the key determinants of CD4+ T cell fate decisions and provide a blueprint for the development of
novel modular biosensors with translational potential.
标题:探索T细胞命运决定的机制基础。
CD 4 + T细胞使用高度敏感和特异性的模块化生物传感器来调查身体的微生物病原体
或肿瘤。TCR是这种行为的主要媒介。检测抗原上MHC的含量
提呈细胞的肽(pMHC)来源于微生物病原体或肿瘤,并中继pMHC特异性
信息通过细胞膜传递到10个基于免疫受体酪氨酸的激活基序(ITAM),
相关的CD 3 γε、CD 3 δε和CD 3 γ ε信号传导模块。CD 4将Lck募集至TCR-CD 3复合物,
MHC的同时结合。通过Lck的ITAM磷酸化的数量和质量提供了ITAM磷酸化的基础。
指导CD 4 + T细胞命运决定。然而,TCR-CD 3-pMHC-CD 4的单个亚基如何与TCR-CD 3-pMHC-CD 4的亚基结合,
宏复合体的配合和共同作用,以推动CD 4 + T细胞的命运决定仍然是完全确定的。我们
工作假设是这些分子以与较不复杂的受体类似的机械原理起作用
系统,如细胞因子受体,由此受体相关的细胞内信号传导酶及其
底物保持在代表“关闭”的空间关系中; pMHC-接合和相互作用
然后,TCR-CD 3复合物和CD 4之间的细胞外相互作用定位细胞内信号传导
结构域以适当的空间关系持续足够的持续时间以启动和增强信号传导。我们
首要目标是了解这种复杂分子机制的内部运作,
或模仿其形态和功能,设计具有独特治疗功能的新型模块化生物传感器。期间
在上一个资助期内,我们建立了多个实验平台,研究
TCR-CD 3亚基的质膜(JM)区。这使我们能够报告一个
一种机械开关,将pMHC特异性信息从TCR-pMHC界面传递到T细胞
细胞膜与CD 3受体信号传导模块的胞质质膜区域的连接。此外,我们执行了
TCR-CD 3-pMHC-CD 4大复合物结构的第一次实验分析,发现
CD 4 JM区邻近CD 3异二聚体,而CD 3 γ-D位于TCR的相对侧。
我们还鉴定了TMD和CD 4细胞外结构域中高度保守的残基,
对于CD 4的Lck独立和Lck依赖功能。最后,我们获得了TCR的功能证据-
我们将其解释为MHC扫描的证据。此次更新的目标
应用是解构TCR-CD 3-pMHC-CD 4大复合物的分子机制,
操作和表征这些机制在体内的后果。我们的工作将产生基本的
深入了解CD 4 + T细胞命运决定的关键决定因素,并为开发
具有平移潜力的新型模块化生物传感器。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The TCR Cα Domain Regulates Responses to Self-pMHC Class II.
- DOI:10.4049/jimmunol.2200377
- 发表时间:2022-11-15
- 期刊:
- 影响因子:0
- 作者:Kim CY;Parrish HL;Kuhns MS
- 通讯作者:Kuhns MS
A Mechanical Switch Couples T Cell Receptor Triggering to the Cytoplasmic Juxtamembrane Regions of CD3ζζ.
- DOI:10.1016/j.immuni.2015.06.018
- 发表时间:2015-08-18
- 期刊:
- 影响因子:32.4
- 作者:Lee MS;Glassman CR;Deshpande NR;Badgandi HB;Parrish HL;Uttamapinant C;Stawski PS;Ting AY;Kuhns MS
- 通讯作者:Kuhns MS
A Transmembrane Domain GGxxG Motif in CD4 Contributes to Its Lck-Independent Function but Does Not Mediate CD4 Dimerization.
CD4 中的跨膜结构域 GGxxG 基序有助于其 Lck 独立功能,但不介导 CD4 二聚化。
- DOI:10.1371/journal.pone.0132333
- 发表时间:2015
- 期刊:
- 影响因子:3.7
- 作者:Parrish,HeatherL;Glassman,CalebR;Keenen,MadelineM;Deshpande,NehaR;Bronnimann,MatthewP;Kuhns,MichaelS
- 通讯作者:Kuhns,MichaelS
Bonds Voyage! A Dissociative Model of TCR-CD3 Triggering Is Proposed.
债券之旅!
- DOI:10.1016/j.immuni.2018.11.008
- 发表时间:2018
- 期刊:
- 影响因子:32.4
- 作者:Lichauco,Katrina;Lee,MarkS;Kuhns,MichaelS
- 通讯作者:Kuhns,MichaelS
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael S Kuhns其他文献
Michael S Kuhns的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael S Kuhns', 18)}}的其他基金
Engineering 2nd generation 5MCARs to monitor and treat Type-I Diabetes
设计第二代 5MCAR 来监测和治疗 I 型糖尿病
- 批准号:
10598106 - 财政年份:2022
- 资助金额:
$ 40.36万 - 项目类别:
Engineering and Testing of Biomimetic Stimulators for Therapeutic Applications
用于治疗应用的仿生刺激器的工程和测试
- 批准号:
10705808 - 财政年份:2022
- 资助金额:
$ 40.36万 - 项目类别:
Adapting 5MCAR technology for the treatment of peripheral T cell lymphoma
采用5MCAR技术治疗外周T细胞淋巴瘤
- 批准号:
10351121 - 财政年份:2022
- 资助金额:
$ 40.36万 - 项目类别:
Engineering and Testing of Biomimetic Stimulators for Therapeutic Applications
用于治疗应用的仿生刺激器的工程和测试
- 批准号:
10570359 - 财政年份:2022
- 资助金额:
$ 40.36万 - 项目类别:
Engineering 2nd generation 5MCARs to monitor and treat Type-I Diabetes
设计第二代 5MCAR 来监测和治疗 I 型糖尿病
- 批准号:
10435625 - 财政年份:2022
- 资助金额:
$ 40.36万 - 项目类别:
Adapting 5MCAR technology for the treatment of peripheral T cell lymphoma
采用5MCAR技术治疗外周T细胞淋巴瘤
- 批准号:
10543167 - 财政年份:2022
- 资助金额:
$ 40.36万 - 项目类别:
Inducing Tolerance with 5-Module chimeric Antigen Receptor (5MCAR) T Cells
使用 5 模块嵌合抗原受体 (5MCAR) T 细胞诱导耐受
- 批准号:
10247395 - 财政年份:2020
- 资助金额:
$ 40.36万 - 项目类别:
Development of Cellular Tools and Techniques to Identify Low Affinity T Cells
开发识别低亲和力 T 细胞的细胞工具和技术
- 批准号:
10259675 - 财政年份:2020
- 资助金额:
$ 40.36万 - 项目类别:
Development of Cellular Tools and Techniques to Identify Low Affinity T Cells
开发识别低亲和力 T 细胞的细胞工具和技术
- 批准号:
9974912 - 财政年份:2020
- 资助金额:
$ 40.36万 - 项目类别:
Probing the mechanistic basis for T cell fate decisions (R01)
探讨T细胞命运决定的机制基础(R01)
- 批准号:
8702920 - 财政年份:2012
- 资助金额:
$ 40.36万 - 项目类别:
相似海外基金
Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
- 批准号:
10751133 - 财政年份:2023
- 资助金额:
$ 40.36万 - 项目类别:
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的微流控精密工程人工抗原呈递细胞
- 批准号:
10696138 - 财政年份:2022
- 资助金额:
$ 40.36万 - 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
- 批准号:
10663066 - 财政年份:2022
- 资助金额:
$ 40.36万 - 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
- 批准号:
10537159 - 财政年份:2022
- 资助金额:
$ 40.36万 - 项目类别:
Analysis of the function of antigen-presenting cells present in the stroma of colorectal cancer and the intracellular microbiome
结直肠癌基质中抗原呈递细胞和细胞内微生物组的功能分析
- 批准号:
21K08723 - 财政年份:2021
- 资助金额:
$ 40.36万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
- 批准号:
10156950 - 财政年份:2021
- 资助金额:
$ 40.36万 - 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
- 批准号:
10631854 - 财政年份:2021
- 资助金额:
$ 40.36万 - 项目类别:
Reprogramming Cancer Cells into Antigen Presenting Cells: Cancer Vaccination with mRNA Enabled by Charge-Altering Releasable Transporters
将癌细胞重编程为抗原呈递细胞:通过改变电荷的可释放转运蛋白实现 mRNA 的癌症疫苗接种
- 批准号:
10153927 - 财政年份:2021
- 资助金额:
$ 40.36万 - 项目类别:
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
- 批准号:
10331830 - 财政年份:2021
- 资助金额:
$ 40.36万 - 项目类别:
Analysis on detrimental interplay between pathogenic helper T cells, inflammatory antigen-presenting cells and disease-associated microglia in chronic pathogenesis of multiple sclerosis
多发性硬化症慢性发病机制中致病性辅助 T 细胞、炎症抗原呈递细胞和疾病相关小胶质细胞之间的有害相互作用分析
- 批准号:
20K16294 - 财政年份:2020
- 资助金额:
$ 40.36万 - 项目类别:
Grant-in-Aid for Early-Career Scientists